BDBM322529 5-[3-[4-(2-thienyl)-1H-imidazol-2-yl]chroman-6-yl]oxy-3,4-dihydro-1H-1,8-naphthyridin-2-one::US10183939, Example 7::USRE49361, Example 7

SMILES O=C1CCc2c(Oc3ccc4OCC(Cc4c3)c3nc(c[nH]3)-c3cccs3)ccnc2N1

InChI Key InChIKey=WCSQDCPCGRYUND-UHFFFAOYSA-N

Data  8 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 8 hits for monomerid = 322529   

LigandPNGBDBM322529(5-[3-[4-(2-thienyl)-1H-imidazol-2-yl]chroman-6-yl]...)
Affinity DataIC50: 4nMAssay Description:To determine whether compounds bind to RAF kinases, they are tested in a competition binding assay. The Invitrogen LanthaScreen Eu binding assay invo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

LigandPNGBDBM322529(5-[3-[4-(2-thienyl)-1H-imidazol-2-yl]chroman-6-yl]...)
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

LigandPNGBDBM322529(5-[3-[4-(2-thienyl)-1H-imidazol-2-yl]chroman-6-yl]...)
Affinity DataIC50: 1.10nMAssay Description:To determine whether compounds bind to RAF kinases, they are tested in a competition binding assay. The Invitrogen LanthaScreen Eu binding assay invo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

LigandPNGBDBM322529(5-[3-[4-(2-thienyl)-1H-imidazol-2-yl]chroman-6-yl]...)
Affinity DataIC50: 0.5nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322529(5-[3-[4-(2-thienyl)-1H-imidazol-2-yl]chroman-6-yl]...)
Affinity DataIC50: 4nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetRAF proto-oncogene serine/threonine-protein kinase(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322529(5-[3-[4-(2-thienyl)-1H-imidazol-2-yl]chroman-6-yl]...)
Affinity DataIC50: 4nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322529(5-[3-[4-(2-thienyl)-1H-imidazol-2-yl]chroman-6-yl]...)
Affinity DataIC50: 1.10nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetRAF proto-oncogene serine/threonine-protein kinase(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322529(5-[3-[4-(2-thienyl)-1H-imidazol-2-yl]chroman-6-yl]...)
Affinity DataIC50: 0.5nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent